Key facts
- This page summarizes John Johnson's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2022, 17:13.
John Johnson - 08 Jun 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)
- Reporting relationship
- Director
- Issuer ticker
- XERS
- Reported as of
- 08 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2022, 17:13:38 UTC
- Prior SEC filing
- 03 Jun 2022
- Next SEC filing
- 24 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Beth Hecht as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Johnson filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 09 Jun 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XERS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +3.1%
- Price
- $0.000000
- Shares after
- 493,312
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XERS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 08 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $2.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.
Footnote F2
Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.